Robert T Peters

This inventor holds 63 USPTO granted patents and 43 published patent applications, plus 8 CIPO patents and 32 EPO patents, primarily in Gene Therapy (CPC class C07K). Top assignees: Bioverativ Therapeutics Inc., Syntonix Pharmaceuticals, Inc., United Parcel Service of America, Inc.. Active years: 2006-2026.

USPTO Granted Patents = 63 (Patent Applications = 43)

% Patents Active = 85.7

CIPO Patents = 8 (Patent Applications = 10)

EPO Patents = 32 (Patent Applications = 49)

Average Co-Inventor Count = 3.7

ph-index = 16

Forward Citations = 1,226(Granted Patents)

Forward Citations (Not Self Cited) = 914(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Atlanta, GA (US) (2006 - 2009)
W. Roxbury, MA (US) (2013)
Kingwood, TX (US) (2016 - 2020)
West Roxbury, MA (US) (2008 - 2022)
Needham, MA (US) (2014 - 2023)

Company Filing History:

40 out of 76

Bioverativ Therapeutics Inc.

patents

10 out of 14

Syntonix Pharmaceuticals, Inc.

patents

4 out of 922

United Parcel Service of America, Inc.

patents

4. 3 out of 5

Biogen Idec Hemophilia Inc.

Exxonmobil Research and Engineering Company

patents

7. 1 out of 1

Biogen Hemophila Inc.

patent

8. 1 out of 2

Biogen Hemophilia Inc.

patents

Years Active: 2006-2026

Loading Chart...

Areas of Expertise:

Factor VIII

Chimeric Proteins

Gene Therapy

Polypeptides

Procoagulant Compounds

Immunoglobulin

Factor IX

Hybrid Polypeptides

Nucleic Acids

Clotting Factors

XTEN

Monomer-Dimer Hybrids

63 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12679882 - OPTIMIZED FACTOR VIII GENE (2026-07-14),

2. 12617839 - Factor VIII chimeric proteins and uses thereof (2026-05-05),

3. 12364774 - Nucleic acid molecules and uses thereof for non-viral gene therapy (2025-07-22),

4. 12275970 - Optimized factor IX gene (2025-04-14),

5. 12186375 - Factor VIII chimeric and hybrid polypeptides, and methods of use thereof (2025-01-07),

6. 12168776 - Nucleic acid molecules and uses thereof (2024-12-17),

7. 11787851 - Optimized factor VIII gene (2023-10-17),

8. 11401322 - Immunoglobulin chimeric monomer-dimer hybrids (2022-08-02),

9. 11370827 - Chimeric factor VIII polypeptides and uses thereof (2022-06-28),

10. 11266720 - Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereof (2022-03-08),

11. 11261437 - Procoagulant compounds (2022-03-01),

12. 11225650 - Methods of using FIX polypeptides (2022-01-18),

13. 11192936 - Factor VIII chimeric proteins and uses thereof (2021-12-07),

14. 11168316 - Chimeric clotting factors (2021-11-09),

15. 11168125 - Immunoglobulin chimeric monomer-dimer hybrids (2021-11-09),

Title: The Inventor Robert T Peters: Pioneering Innovations in Needham

Introduction: Robert T Peters is a distinguished inventor based in Needham, Massachusetts, known for his groundbreaking contributions to various fields through his innovative creations.

Latest Patents: Robert T Peters holds several patents in diverse areas, showcasing his versatility and ingenuity in inventing new solutions to complex problems.

Career Highlights: Throughout his illustrious career, Robert T Peters has consistently pushed the boundaries of innovation, with his inventions making a significant impact in industries such as technology, healthcare, and sustainability.

Collaborations: Robert T Peters has collaborated with leading companies, research institutions, and universities to further develop and commercialize his inventions, demonstrating his ability to work effectively in multidisciplinary teams.

Conclusion: In conclusion, Robert T Peters stands as a visionary inventor whose passion for innovation and dedication to creating meaningful change continue to inspire the next generation of inventors and entrepreneurs.